Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Supports a Letter Written to the Department of Health and Human Services Regarding Evusheld Distribution

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

It is crucial for policymakers understand the importance of ensuring Evusheld, the COVID-19 monoclonal antibody authorized for Pre-Exposure Prophylaxis (PrEP), is both readily available and easily accessible to anyone who qualifies to receive it. This includes all of those living with CLL/SLL, as well as many others who are immunocompromised and deserve protection against COVID-19.

Recently, CLL Society played a key role in working with Congresswoman Sara Jacobs (from California’s 53rd District) to draft a letter to the US Secretary of Health, Xavier Becerra. This letter spoke to the need for the federal government to purchase additional doses of Evusheld and provided some suggestions to improve upon distribution efforts. Although some improvements have already been made, Evusheld remains in short supply and is still difficult to access in many parts of the country. In part due to the imbalanced distribution efforts by the Federal Government. Please review this great example of the much-needed support from our policy makers who are championing these efforts.

Rep Jacobs Evusheld LetterClick here to download